Literature DB >> 33743193

Liver gene therapy and hepatocellular carcinoma: A complex web.

Ype P de Jong1, Roland W Herzog2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33743193      PMCID: PMC8058499          DOI: 10.1016/j.ymthe.2021.03.009

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.

Authors:  Lindsey A George; Margaret V Ragni; John E J Rasko; Leslie J Raffini; Benjamin J Samelson-Jones; Margareth Ozelo; Maria Hazbon; Alexa R Runowski; Jennifer A Wellman; Katie Wachtel; Yifeng Chen; Xavier M Anguela; Klaudia Kuranda; Federico Mingozzi; Katherine A High
Journal:  Mol Ther       Date:  2020-06-10       Impact factor: 11.454

2.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green; Amit G Singal; Elliot B Tapper; Akbar K Waljee; Richard K Sterling; Jordan J Feld; David E Kaplan; Tamar H Taddei; Kristin Berry
Journal:  Gastroenterology       Date:  2019-07-26       Impact factor: 22.682

3.  Adeno-associated virus in the liver: natural history and consequences in tumour development.

Authors:  Tiziana La Bella; Sandrine Imbeaud; Camille Peneau; Iadh Mami; Shalini Datta; Quentin Bayard; Stefano Caruso; Theo Z Hirsch; Julien Calderaro; Guillaume Morcrette; Catherine Guettier; Valerie Paradis; Giuliana Amaddeo; Alexis Laurent; Laurent Possenti; Laurence Chiche; Paulette Bioulac-Sage; Jean-Frederic Blanc; Eric Letouze; Jean-Charles Nault; Jessica Zucman-Rossi
Journal:  Gut       Date:  2019-08-02       Impact factor: 23.059

4.  Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.

Authors:  Jean-Charles Nault; Shalini Datta; Sandrine Imbeaud; Andrea Franconi; Maxime Mallet; Gabrielle Couchy; Eric Letouzé; Camilla Pilati; Benjamin Verret; Jean-Frédéric Blanc; Charles Balabaud; Julien Calderaro; Alexis Laurent; Mélanie Letexier; Paulette Bioulac-Sage; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-08-24       Impact factor: 38.330

5.  A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells.

Authors:  Giang N Nguyen; John K Everett; Samita Kafle; Aoife M Roche; Hayley E Raymond; Jacob Leiby; Christian Wood; Charles-Antoine Assenmacher; Elizabeth P Merricks; C Tyler Long; Haig H Kazazian; Timothy C Nichols; Frederic D Bushman; Denise E Sabatino
Journal:  Nat Biotechnol       Date:  2020-11-16       Impact factor: 54.908

6.  AAV Joins the Rank of Genotoxic Vectors.

Authors:  Utpal P Davé; Kenneth Cornetta
Journal:  Mol Ther       Date:  2021-01-20       Impact factor: 11.454

  6 in total
  6 in total

Review 1.  Evaluating the state of the science for adeno-associated virus integration: An integrated perspective.

Authors:  Denise E Sabatino; Frederic D Bushman; Randy J Chandler; Ronald G Crystal; Beverly L Davidson; Ricardo Dolmetsch; Kevin C Eggan; Guangping Gao; Irene Gil-Farina; Mark A Kay; Douglas M McCarty; Eugenio Montini; Adora Ndu; Jing Yuan
Journal:  Mol Ther       Date:  2022-06-10       Impact factor: 12.910

Review 2.  Cryo-electron Microscopy of Adeno-associated Virus.

Authors:  Scott M Stagg; Craig Yoshioka; Omar Davulcu; Michael S Chapman
Journal:  Chem Rev       Date:  2022-05-16       Impact factor: 72.087

3.  Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.

Authors:  Chenghua Song; Jia Zhang; Ruichao Wen; Qingshan Li; Jiaxuan Zhou; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Mater Today Bio       Date:  2022-07-06

Review 4.  Evolving therapies in neuronopathic LSDs: opportunities and challenges.

Authors:  Deepa S Rajan; Maria L Escolar
Journal:  Metab Brain Dis       Date:  2022-04-20       Impact factor: 3.655

5.  AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study.

Authors:  Huimin Hu; Rosario Mosca; Elida Gomero; Diantha van de Vlekkert; Yvan Campos; Leigh E Fremuth; Scott A Brown; Jason A Weesner; Ida Annunziata; Alessandra d'Azzo
Journal:  Mol Ther Methods Clin Dev       Date:  2021-10-28       Impact factor: 6.698

Review 6.  A versatile toolkit for overcoming AAV immunity.

Authors:  Xuefeng Li; Xiaoli Wei; Jinduan Lin; Li Ou
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.